Wang Zhengshi, Li Yao, Jiang Wenli, Yan Jie, Dai Jiaqi, Jiao Binghua, Yin Zhiqiang, Zhang Yun
Thyroid Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Shanghai Center for Thyroid Diseases, Shanghai, China.
Front Oncol. 2019 May 22;9:409. doi: 10.3389/fonc.2019.00409. eCollection 2019.
Consensus-based clinical guidelines recommend that simple cholecystectomy (SC) is adequate for T1a gallbladder adenocarcinoma (GBA), but extended cholecystectomy (EC), SC plus lymphatic dissection, should be considered for T1b and more advanced GBA. Whether lymphatic dissection is necessary for the treatment of T1b GBA remains controversial. This study attempts to better define the current criteria for local treatment of T1b GBA, by examining the relationship between lymph node (LN) metastasis and tumor size in such patients. Clinical data from patients with T1b GBA receiving curative surgical treatment between 2004 and 2015 were collected from the Surveillance, Epidemiology, and End Results (SEER) database. Baseline characteristics for the entire cohort were described, and overall survival (OS) and cancer-specific survival (CSS) were analyzed with the Kaplan-Meier method. In total, 277 patients were enrolled for further analysis; 127 underwent lymphadenectomy. Among them, 23 patients had tumors <1 cm in diameter, none of which had LN metastasis; 104 patients had tumors ≥1 cm, 15 of which had positive LNs. In the group with tumor size <1 cm, there was no significant survival difference between treatment with SC or EC ( = 0.694). A clinical benefit was observed in T1b GBA patients with a tumor size ≥1 cm receiving EC vs. those receiving SC ( = 0.012). SC was adequate for treatment of T1b GBA < 1 cm in diameter. This evidence may be included as part of current guidelines.
基于共识的临床指南建议,单纯胆囊切除术(SC)适用于T1a期胆囊腺癌(GBA),但对于T1b期及更晚期的GBA,应考虑扩大胆囊切除术(EC),即SC加淋巴结清扫术。对于T1b期GBA的治疗是否有必要进行淋巴结清扫仍存在争议。本研究试图通过检查此类患者的淋巴结(LN)转移与肿瘤大小之间的关系,更好地界定目前T1b期GBA局部治疗的标准。从监测、流行病学和最终结果(SEER)数据库中收集了2004年至2015年间接受根治性手术治疗的T1b期GBA患者的临床数据。描述了整个队列的基线特征,并采用Kaplan-Meier方法分析了总生存期(OS)和癌症特异性生存期(CSS)。总共纳入并进一步分析了277例患者;其中127例行淋巴结切除术。其中,23例患者肿瘤直径<1 cm,均无LN转移;104例患者肿瘤直径≥1 cm,其中15例LN阳性。在肿瘤大小<1 cm的组中,SC或EC治疗之间的生存差异无统计学意义(P = 0.694)。观察到肿瘤大小≥1 cm的T1b期GBA患者接受EC治疗与接受SC治疗相比具有临床获益(P = 0.012)。SC足以治疗直径<1 cm的T1b期GBA。这一证据可纳入当前指南。